{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T02:21:20Z","timestamp":1789093280728,"version":"build-2803163510"},"reference-count":46,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1,9]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Children with ETV6::RUNX1 or high-hyperdiploid B-cell acute lymphoblastic leukemia (B-ALL) have favorable outcomes. The St. Jude (SJ) classification considers these patients low risk, regardless of their National Cancer Institute (NCI) risk classification, except when there is slow minimal residual disease (MRD) response or central nervous system\/testicular involvement. We analyzed outcomes in children (aged 1-18.99 years) with these genotypes in the SJ Total XV\/XVI studies (2000-2017). Patients with ETV6::RUNX1 (n\u00a0=\u00a0222) or high-hyperdiploid (n\u00a0=\u00a0296) B-ALL had 5-year event-free survival (EFS) of 97.7%\u2009\u00b1\u20091.1% and 94.7%\u2009\u00b1\u20091.4%, respectively. For ETV6::RUNX1, EFS was comparable between NCI standard-risk and high-risk patients and between SJ low-risk and standard-risk patients. Of the 40 NCI high-risk patients, 37 who received SJ low-risk therapy had excellent EFS (97.3%\u2009\u00b1\u20092.8%). For high-hyperdiploid B-ALL, NCI high-risk patients had worse EFS than standard-risk patients (87.6%\u2009\u00b1\u20094.5% vs 96.4%\u2009\u00b1\u20091.3%; P\u00a0=\u00a0.016). EFS was similar for NCI standard-risk and high-risk patients classified as SJ low risk (96.0%\u2009\u00b1\u20091.5% and 96.9%\u2009\u00b1\u20093.2%; P\u00a0=\u00a0.719). However, EFS was worse for NCI high-risk patients than for NCI standard-risk patients receiving SJ standard\/high-risk therapy (77.4%\u2009\u00b1\u20098.2% vs 98.0%\u2009\u00b1\u20092.2%; P\u00a0=\u00a0.004). NCI high-risk patients with ETV6::RUNX1 or high-hyperdiploid B-ALL who received SJ low-risk therapy had lower incidences of thrombosis (P\u00a0=\u00a0.013) and pancreatitis (P\u00a0=\u00a0.011) than those who received SJ standard\/high-risk therapy. MRD-directed therapy yielded excellent outcomes, except for NCI high-risk high-hyperdiploid B-ALL patients with slow MRD response, who require new treatment approaches. Among NCI high-risk patients, 93% with ETV6::RUNX1 and 54% with high-hyperdiploid B-ALL experienced excellent outcomes with a low-intensity regimen. These trials were registered at www.clinicaltrials.gov as #NCT00137111 and #NCT00549848.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2024024936","type":"journal-article","created":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T17:48:05Z","timestamp":1727200085000},"page":"190-201","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":20,"title":["Outcomes in patients with <i>ETV6<\/i>::<i>RUNX1<\/i> or high-hyperdiploid B-ALL treated in the St. Jude Total\u00a0Therapy XV\/XVI studies"],"prefix":"10.1182","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0278-9175","authenticated-orcid":false,"given":"Katelyn","family":"Purvis","sequence":"first","affiliation":[{"name":"1Department of Oncology, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinmei","family":"Zhou","sequence":"additional","affiliation":[{"name":"2Department of Biostatistics, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8113-8180","authenticated-orcid":false,"given":"Seth E.","family":"Karol","sequence":"additional","affiliation":[{"name":"1Department of Oncology, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9885-3527","authenticated-orcid":false,"given":"Jeffrey E.","family":"Rubnitz","sequence":"additional","affiliation":[{"name":"1Department of Oncology, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9956-5647","authenticated-orcid":false,"given":"Raul C.","family":"Ribeiro","sequence":"additional","affiliation":[{"name":"1Department of Oncology, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn","family":"Lee","sequence":"additional","affiliation":[{"name":"3Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children\u2019s Research Hospital, Memphis, TN"},{"name":"4Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore"},{"name":"5Khoo Teck Puat\u2013National University Children\u2019s Medical Institute, National University Health System, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun J.","family":"Yang","sequence":"additional","affiliation":[{"name":"3Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Paul","family":"Bowman","sequence":"additional","affiliation":[{"name":"6Department of Pediatrics, Cook Children\u2019s Medical Center, Fort Worth, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0073-0666","authenticated-orcid":false,"given":"Lu","family":"Wang","sequence":"additional","affiliation":[{"name":"7Department of Pathology, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3901-3274","authenticated-orcid":false,"given":"Stephanie B.","family":"Dixon","sequence":"additional","affiliation":[{"name":"1Department of Oncology, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7626-4043","authenticated-orcid":false,"given":"Kathryn G.","family":"Roberts","sequence":"additional","affiliation":[{"name":"7Department of Pathology, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9930-8499","authenticated-orcid":false,"given":"Qingsong","family":"Gao","sequence":"additional","affiliation":[{"name":"7Department of Pathology, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Cheng","sequence":"additional","affiliation":[{"name":"2Department of Biostatistics, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1871-1850","authenticated-orcid":false,"given":"Charles G.","family":"Mullighan","sequence":"additional","affiliation":[{"name":"7Department of Pathology, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sima","family":"Jeha","sequence":"additional","affiliation":[{"name":"1Department of Oncology, St. Jude Children\u2019s Research Hospital, Memphis, TN"},{"name":"8Department of Global Pediatric Medicine, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0303-5658","authenticated-orcid":false,"given":"Ching-Hon","family":"Pui","sequence":"additional","affiliation":[{"name":"1Department of Oncology, St. Jude Children\u2019s Research Hospital, Memphis, TN"},{"name":"8Department of Global Pediatric Medicine, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0605-7342","authenticated-orcid":false,"given":"Hiroto","family":"Inaba","sequence":"additional","affiliation":[{"name":"1Department of Oncology, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"16","key":"2025010916210530200_bib1","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1056\/NEJMra1400972","article-title":"Acute lymphoblastic leukemia in children","volume":"373","author":"Hunger","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"2025010916210530200_bib2","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.3324\/haematol.2020.247031","article-title":"Pediatric acute lymphoblastic leukemia","volume":"105","author":"Inaba","year":"2020","journal-title":"Haematologica"},{"issue":"2","key":"2025010916210530200_bib3","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/leu.2011.227","article-title":"ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy","volume":"26","author":"Bhojwani","year":"2012","journal-title":"Leukemia"},{"issue":"14","key":"2025010916210530200_bib4","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1200\/JCO.20.02370","article-title":"Favorable trisomies and ETV6-RUNX1 predict cure in low-risk B-cell acute lymphoblastic leukemia: results from Children's Oncology Group trial AALL0331","volume":"39","author":"Mattano","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"13","key":"2025010916210530200_bib5","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1200\/JCO.2007.14.3552","article-title":"Prospective analysis of TEL gene rearrangements in childhood acute lymphoblastic leukemia: a Children's Oncology Group study","volume":"26","author":"Rubnitz","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"2025010916210530200_bib6","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1038\/leu.2013.136","article-title":"Long-term follow-up of ETV6-RUNX1 ALL reveals that NCI risk, rather than secondary genetic abnormalities, is the key risk factor","volume":"27","author":"Enshaei","year":"2013","journal-title":"Leukemia"},{"issue":"11","key":"2025010916210530200_bib7","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1182\/blood-2005-08-3451","article-title":"Prospective analysis of TEL\/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01","volume":"107","author":"Loh","year":"2006","journal-title":"Blood"},{"issue":"12","key":"2025010916210530200_bib8","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1182\/blood.V79.12.3316.bloodjournal79123316","article-title":"Trisomy of leukemic cell chromosomes 4 and 10 identifies children with B-progenitor cell acute lymphoblastic leukemia with a very low risk of treatment failure: a Pediatric Oncology Group study","volume":"79","author":"Harris","year":"1992","journal-title":"Blood"},{"issue":"13","key":"2025010916210530200_bib9","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1182\/blood-2012-06-437681","article-title":"Hyperdiploidy with 58-66 chromosomes in childhood B-acute lymphoblastic leukemia is highly curable: 58951 CLG-EORTC results","volume":"121","author":"Dastugue","year":"2013","journal-title":"Blood"},{"issue":"4","key":"2025010916210530200_bib10","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/2643-3230.BCD-20-0229","article-title":"Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease-directed therapy","volume":"2","author":"Jeha","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"4","key":"2025010916210530200_bib11","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S1470-2045(15)70082-3","article-title":"Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study","volume":"16","author":"Pui","year":"2015","journal-title":"Lancet Oncol"},{"issue":"1","key":"2025010916210530200_bib12","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1200\/JCO.2017.74.0449","article-title":"Genotype-specific minimal residual disease interpretation improves stratification in pediatric acute lymphoblastic leukemia","volume":"36","author":"O'Connor","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2025010916210530200_bib13","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/leu.2016.234","article-title":"Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with response-adapted therapy","volume":"31","author":"Pui","year":"2017","journal-title":"Leukemia"},{"issue":"26","key":"2025010916210530200_bib14","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1056\/NEJMoa0900386","article-title":"Treating childhood acute lymphoblastic leukemia without cranial irradiation","volume":"360","author":"Pui","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"35","key":"2025010916210530200_bib15","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1200\/JCO.19.01692","article-title":"Improved CNS control of childhood acute lymphoblastic leukemia without cranial irradiation: St Jude total therapy study 16","volume":"37","author":"Jeha","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"35","key":"2025010916210530200_bib16","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1200\/JCO.23.00880","article-title":"Prognostic and pharmacotypic heterogeneity of hyperdiploidy in childhood ALL","volume":"41","author":"Lee","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2025010916210530200_bib17","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1470-2045(12)70600-9","article-title":"Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial","volume":"14","author":"Vora","year":"2013","journal-title":"Lancet Oncol"},{"issue":"6","key":"2025010916210530200_bib18","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1038\/s41375-022-01547-8","article-title":"RNAseqCNV: analysis of large-scale copy number variations from RNA-seq data","volume":"36","author":"Ba\u0159inka","year":"2022","journal-title":"Leukemia"},{"issue":"7137","key":"2025010916210530200_bib19","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/nature05690","article-title":"Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia","volume":"446","author":"Mullighan","year":"2007","journal-title":"Nature"},{"issue":"282","key":"2025010916210530200_bib20","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J\u00a0Am Stat Assoc"},{"issue":"4","key":"2025010916210530200_bib21","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"Mantel","year":"1959","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"2025010916210530200_bib22","author":"Kalbfleisch","year":"1980"},{"issue":"3","key":"2025010916210530200_bib23","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A\u00a0class of K-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Statist"},{"issue":"3","key":"2025010916210530200_bib24","first-page":"1094","article-title":"TEL\/AML1 gene fusion is related to in\u00a0vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia","volume":"96","author":"Ramakers-van Woerden","year":"2000","journal-title":"Blood"},{"issue":"1","key":"2025010916210530200_bib25","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41591-022-02112-7","article-title":"Pharmacotypes across the genomic landscape of pediatric acute lymphoblastic leukemia and impact on treatment response","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"},{"issue":"3","key":"2025010916210530200_bib26","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2017.74.4946","article-title":"Reduced-intensity delayed intensification in standard-risk pediatric acute lymphoblastic leukemia defined by undetectable minimal residual disease: results of an international randomized trial (AIEOP-BFM ALL 2000)","volume":"36","author":"Schrappe","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2025010916210530200_bib27","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/leu.2009.260","article-title":"Long-term results of Tokyo Children's Cancer Study Group trials for childhood acute lymphoblastic leukemia, 1984-1999","volume":"24","author":"Tsuchida","year":"2010","journal-title":"Leukemia"},{"issue":"3","key":"2025010916210530200_bib28","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/leu.2016.274","article-title":"Long-term outcome of 6-month maintenance chemotherapy for acute lymphoblastic leukemia in children","volume":"31","author":"Kato","year":"2017","journal-title":"Leukemia"},{"issue":"22","key":"2025010916210530200_bib29","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1200\/JCO.2015.64.6364","article-title":"Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: study ALL10 from the Dutch Childhood Oncology Group","volume":"34","author":"Pieters","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"20","key":"2025010916210530200_bib30","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.1200\/JCO.22.02347","article-title":"Anthracycline-free protocol for favorable-risk childhood ALL: a noninferiority comparison between Malaysia-Singapore ALL 2003 and ALL 2010 studies","volume":"41","author":"Ariffin","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"25","key":"2025010916210530200_bib31","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.1200\/JCO.22.02705","article-title":"Improved outcome for ALL by prolonging therapy for IKZF1 deletion and decreasing therapy for other risk groups","volume":"41","author":"Pieters","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"2025010916210530200_bib32","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1038\/s41588-022-01159-z","article-title":"The genomic landscape of pediatric acute lymphoblastic leukemia","volume":"54","author":"Brady","year":"2022","journal-title":"Nat Genet"},{"issue":"3","key":"2025010916210530200_bib33","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/bjh.18552","article-title":"Characterisation of children and adolescents with acute lymphoblastic leukaemia who presented without peripheral blood blasts at diagnosis","volume":"200","author":"Mangum","year":"2023","journal-title":"Br J Haematol"},{"issue":"3","key":"2025010916210530200_bib34","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1001\/jamaoncol.2021.6826","article-title":"Association of genetic ancestry with the molecular subtypes and prognosis of childhood acute lymphoblastic leukemia","volume":"8","author":"Lee","year":"2022","journal-title":"JAMA Oncol"},{"issue":"36","key":"2025010916210530200_bib35","doi-asserted-by":"crossref","first-page":"4228","DOI":"10.1200\/JCO.22.00245","article-title":"Time to cure for childhood and young adult acute lymphoblastic leukemia is independent of early risk factors: long-term follow-up of the UKALL2003 trial","volume":"40","author":"Moorman","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"2025010916210530200_bib36","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1056\/NEJMoa1110169","article-title":"Outcomes after induction failure in childhood acute lymphoblastic leukemia","volume":"366","author":"Schrappe","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"2025010916210530200_bib37","doi-asserted-by":"crossref","first-page":"6600","DOI":"10.1172\/JCI140797","article-title":"Pharmacogenomics of intracellular methotrexate polyglutamates in patients' leukemia cells in\u00a0vivo","volume":"130","author":"Lopez-Lopez","year":"2020","journal-title":"J\u00a0Clin Invest"},{"issue":"3","key":"2025010916210530200_bib38","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1182\/blood.V85.3.751.bloodjournal853751","article-title":"Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: results of an in\u00a0vitro study","volume":"85","author":"Kaspers","year":"1995","journal-title":"Blood"},{"issue":"11","key":"2025010916210530200_bib39","doi-asserted-by":"crossref","first-page":"e828","DOI":"10.1016\/S2352-3026(21)00304-5","article-title":"Defining low-risk high hyperdiploidy in patients with paediatric acute lymphoblastic leukaemia: a retrospective analysis of data from the UKALL97\/99 and UKALL2003 clinical trials","volume":"8","author":"Enshaei","year":"2021","journal-title":"Lancet Haematol"},{"issue":"5","key":"2025010916210530200_bib40","doi-asserted-by":"crossref","first-page":"e875","DOI":"10.1097\/HS9.0000000000000875","article-title":"The prognostic effect of IKZF1 deletions in ETV6::RUNX1 and high hyperdiploid childhood acute lymphoblastic leukemia","volume":"7","author":"\u00d8stergaard","year":"2023","journal-title":"Hemasphere"},{"issue":"8","key":"2025010916210530200_bib41","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41375-024-02277-9","article-title":"Diagnostic and treatment strategies for pediatric acute lymphoblastic leukemia in low- and middle-income countries","volume":"38","author":"Rujkijyanont","year":"2024","journal-title":"Leukemia"},{"issue":"22","key":"2025010916210530200_bib42","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1182\/blood-2018-01-827949","article-title":"Thromboembolism in acute lymphoblastic leukemia: results of NOPHO ALL2008 protocol treatment in patients aged 1 to 45 years","volume":"131","author":"Rank","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2025010916210530200_bib43","first-page":"53","article-title":"Genomic analysis of venous thrombosis in children with acute lymphoblastic leukemia from diverse ancestries","volume":"109","author":"Zheng","year":"2024","journal-title":"Haematologica"},{"issue":"18","key":"2025010916210530200_bib44","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1200\/JCO.2015.64.5812","article-title":"Clinical and genetic risk factors for acute pancreatitis in patients with acute lymphoblastic leukemia","volume":"34","author":"Liu","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2025010916210530200_bib45","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1200\/JCO.19.02208","article-title":"Asparaginase-associated pancreatitis in acute lymphoblastic leukemia: results from the NOPHO ALL2008 treatment of patients 1-45 years of age","volume":"38","author":"Rank","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"29","key":"2025010916210530200_bib46","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1200\/JCO.20.00493","article-title":"Reduced morbidity and mortality in survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study","volume":"38","author":"Dixon","year":"2020","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/2\/190\/2350412\/blood_bld-2024-024936-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/2\/190\/2350412\/blood_bld-2024-024936-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T16:21:37Z","timestamp":1736439697000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/145\/2\/190\/517953\/Outcomes-in-patients-with-ETV6-RUNX1-or-high"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,9]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,1,9]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024024936","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,9]]}}}